SCHEMBL43675

SCHEMBL43675

CC([C]=O)Oc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 1/20 0.42
MTNR1B P49286 1/20 0.42
GAA P10253 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
PKM P14618 1/20 0.41
CYP2C19 P33261 1/20 0.41
KDM4E B2RXH2 1/20 0.39
KMT2A Q03164 3/20 0.39
LMNA P02545 2/20 0.39
MEN1 O00255 2/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39
HPGD P15428 1/20 0.39
CA4 P22748 1/20 0.39
CHRNB4 P30926 2/20 0.37
CHRNA3 P32297 2/20 0.37
ADRA2A P08913 1/20 0.37
ADRA2B P18089 1/20 0.37
ADRA2C P18825 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9353539 1.00 MTNR1A (0.42) MTNR1AMTNR1BGAACYP1A2CYP2C9
SCHEMBL5803766 0.80 TAS1R3 (0.48) MTNR1AMTNR1BGAAPKMKDM4E
SCHEMBL8733198 0.79 POLB (0.41) MTNR1AMTNR1BGAACYP1A2CYP2C9
SCHEMBL8889549 0.78 RAB9A (0.40) KDM4EKMT2AMEN1HPGD
SCHEMBL11328816 0.78 LDHA (0.47) GAAKDM4EKMT2ALMNAMEN1
SCHEMBL11685356 0.78 TDP1 (0.43) KMT2AALDH1A1HPGDMAOAMAOB
SCHEMBL446679 0.78 MTNR1A (0.40) MTNR1AMTNR1BGAACYP1A2CYP2C9
SCHEMBL97275 0.78 POLB (0.43) GAACYP1A2CYP2C9CYP2C19KDM4E
SCHEMBL9415979 0.78 ESR2 (0.41) GAACYP1A2CYP2C9PKMCYP2C19
SCHEMBL7419291 0.78 CYP1A2 (0.48) CYP1A2KMT2ALMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1406 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114933620-A Azithromycin derivatives having epithelial barrier enhancing properties 艾比恩多制药有限责任公司 2022-08-23 CN claimed
US-20220106349-A1 Compounds EPIENDO PHARMACEUTICALS EHF (IS) 2022-04-07 US claimed
US-11236120-B2 Azithromycin derivatives with epithelial barrier enhancement properties EPIENDO PHARMACEUTICALS EHF (IS) 2022-02-01 US claimed
US-20200317710-A1 Azithromycin Derivatives With Epithelial Barrier Enhancement Properties EPIENDO PHARMACEUTICALS EHF (IS) 2020-10-08 US claimed
EP-3708573-A1 AZITHROMYCIN DERIVATIVES WITH EPITHELIAL BARRIER ENHANCEMENT PROPERTIES EpiEndo Pharmaceuticals ehf. (IS) 2020-09-16 EP claimed
US-10723752-B2 Azithromycin derivatives with epithelial barrier enhancement properties EPIENDO PHARMACEUTICALS EHF (IS) 2020-07-28 US claimed
EP-3377511-B1 AZITHROMYCIN DERIVATIVES WITH EPITHELIAL BARRIER ENHANCEMENT PROPERTIES EPIENDO PHARMACEUTICALS EHF (IS) 2020-05-13 EP claimed
US-20180354981-A1 Azithromycin Derivatives With Epithelial Barrier Enhancement Properties EPI-ENDO PHARMACEUTICALS EHF (IS) 2018-12-13 US claimed
EP-3377511-A1 AZITHROMYCIN DERIVATIVES WITH EPITHELIAL BARRIER ENHANCEMENT PROPERTIES Epi-endo Pharmaceuticals Ehf. (IS) 2018-09-26 EP claimed
EP-1512397-B1 O-SUBSTITUTED HYDROXYARYL DERIVATIVES INST MED MOLECULAR DESIGN INC (JP) 2014-10-08 EP claimed
US-4438136-A INHIBITION OF THROMBOXANE ACTIVITY NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1984-03-20 US claimed
EP-0094498-A2 Antiatherosclerotic 1-piperazine derivatives AMERICAN CYANAMID COMPANY (US) 1983-11-23 EP claimed
EP-0013608-B1 SUBSTITUTED BICYCLO (2,2,1)HEPTANES AND HEPT-2-ENES AND THEIR PHARMACEUTICAL COMPOSITIONS NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1983-06-15 EP claimed
US-4269773-A CEPHALOSPORINS SHIONOGI & CO., LTD. (JP) 1981-05-26 US claimed
US-4267340-A BACTERICIDES; SYNTHESIS OF PENICILLINS AND CEPHALOSPORINS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-05-12 US claimed
EP-0003584-B1 PHENOXYPROPANOIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES BAYER AG (DE) 1981-01-21 EP claimed
US-4070458-A MICRBIAL ENZYME SANRAKU-OCEAN CO., LTD. (JA) 1978-01-24 US claimed
US-4055468-A TETRAPEPTIDE SANRAKU-OCEAN CO., LTD. (JA) 1977-10-25 US claimed
US-4009159-A PENICILLINS FUJISAWA PHARMACEUTICAL CO., LTD. (JA) 1977-02-22 US claimed
US-3993646-A Process for the ring expansion of penicillins to cephalosporin compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JA) 1976-11-23 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220106349-A1 Compounds CFTR, AQP1, CTSA MTNR1A 1638/4885MTNR1B 1343/4885GAA 130/4885
US-11236120-B2 Azithromycin derivatives with epithelial barrier enhancement properties CFTR, AQP1, CTSA MTNR1A 1652/4885MTNR1B 1655/4885GAA 315/4885
US-20180354981-A1 Azithromycin Derivatives With Epithelial Barrier Enhancement Properties CFTR, AQP1, CTSA MTNR1A 1652/4885MTNR1B 1655/4885GAA 315/4885
US-20200317710-A1 Azithromycin Derivatives With Epithelial Barrier Enhancement Properties CFTR, AQP1, CTSA MTNR1A 1652/4885MTNR1B 1655/4885GAA 315/4885
US-10723752-B2 Azithromycin derivatives with epithelial barrier enhancement properties CFTR, AQP1, CTSA MTNR1A 1652/4885MTNR1B 1655/4885GAA 315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.